Skip to main content
SpringerLink
Log in

Multidrug resistance in lung cancer

  • Chapter
Lung Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 72))

Abstract

Lung cancer is divided into four major histological types: squamous cell carcinomas, adenocarcinomas, and large cell carcinomas, which are collectively referred to as non-small cell lung cancers (NSCLC), and a distinct type of lung cancer, small cell lung cancer (SCLC) [1]. Surgery, radiotherapy, and chemotherapy are used for the treatment of lung cancer, but long-term survival is obtained in only 5% to 10% of the patients. Thus, improvements in lung cancer therapy are urgently required [2,3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 429.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 549.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Minna JD, Pass H, Glatstein E, Ihde DC. 1989. Cancer of the lung. In Cancer Principles and Practice of Oncology, vol. 1, VT DeVita, S Hellman, and SA Rosenberg (eds.). J.B. Lippincott: Philadelphia, pp. 591–705.

    Google Scholar 

  2. Bleehen NM. 1990. Lung cancer — still a long road ahead. Br J Cancer 61:493–494.

    Article  PubMed  CAS  Google Scholar 

  3. Kristjansen PEG, Hansen HH. 1990. Management of small cell lung cancer: a summary of the Third International Association for the Study of Lung Cancer Workshop on small cell lung cancer. J Natl Cancer Inst 82:263–266.

    Article  PubMed  CAS  Google Scholar 

  4. Goldie JH, Coldman AJ. 1985. Genetic instability in the development of drug resistance. Semin Oncol 12:222-230

    Google Scholar 

  5. Juranka PF, Zastawny RL, Ling V. 1989. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 3:2583–2592.

    PubMed  CAS  Google Scholar 

  6. Choi K, Frommel TO, Kaplan Stern R, Perez CF, Kriegler M, Tsuruo T, Roninson IR. 1991. Multidrug resistance after retroviral transfer of the human MDR1 gene correlates with P-glycoprotein density in the plasma membrane and is not affected by cytotoxic selection. Proc Natl Acad Sci USA 88:7386–7390.

    Article  PubMed  CAS  Google Scholar 

  7. Mickisch GH, Pastan I, Gottesman MM. 1991. Multidrug resistant transgenic mice as a novel pharmacologic tool. BioEssays 13:381–387.

    Article  PubMed  CAS  Google Scholar 

  8. Cole SPC, Bhardwaj G, Gerlach JH, et al. 1992. Overexpression of a transporter gene in a multidrug-resistant human lung cancer line. Science 258:1650–1654.

    Article  PubMed  CAS  Google Scholar 

  9. Versantvoort CHM, Broxterman HJ, Pinedo HM, De Vries EGE, Feller N, Kuiper CM, Lankelma J. 1992. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res 52:17–23.

    PubMed  CAS  Google Scholar 

  10. Barrand MA, Rhodes T, Center MS, Twentyman PR. 1993. Chemosensitisation and drug accumulation of cyclosporin A, PSC 833 and verapamil in human MDR large cell lung cancer cells expressing a 190 kD membrane protein distinct from P-glycoprotein. Eur J Cancer 29A:408–415.

    Article  PubMed  CAS  Google Scholar 

  11. Beck WT. 1990. Multidrug resistance and its circumvention. Eur J Cancer 26:513–515.

    Article  PubMed  CAS  Google Scholar 

  12. Dalton WS. 1993. Drug resistance modulation in the laboratory and the clinic. Semin Oncol 20:64–69.

    PubMed  CAS  Google Scholar 

  13. Kaye SB. 1993. P-glycoprotein (P-gp) and drug resistance — time for reappraisal? Br J Cancer 67:641–643.

    Article  PubMed  CAS  Google Scholar 

  14. Dietel M, Bals U, Schaefer B, Herzig I, Arps H, Zabel M. 1993. In vitro prediction of cytostatic drug resistance in primary cell cultures of solid malignant tumours. Eur J Cancer 29A:416–420.

    Article  PubMed  CAS  Google Scholar 

  15. Miller TP, Young LA, Perrot L, Salmon SE. 1984. Feasibility of a prospective randomized correlative trial of advanced non-small cell lung cancer using the human tumor clonogenic assay. In Human Tumor Cloning, SE Salmon and JM Trent (eds.). Grune and Stratton: Orlando, FL, pp. 535–542.

    Google Scholar 

  16. Weisenthal LM. 1992. Antineoplastic drug screening belongs in the laboratory, not in the clinic. J Natl Cancer Inst 84:466–469.

    Article  PubMed  CAS  Google Scholar 

  17. Wilbur DW, Camacho ES, Hilliard DA, Dill PL, Weisenthal LM. 1992. Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill. Br J Cancer 65:27–32.

    Article  PubMed  CAS  Google Scholar 

  18. Gazdar AF, Steinberg SM, Russell EK, et al. 1990. Correlation of in vitro drug-sensitivity testing with respons to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J Natl Cancer Inst 82:117–124.

    Article  PubMed  CAS  Google Scholar 

  19. De Vries EGE, Meijer C, Mulder NH, Postmus PE. 1987. In vitro chemosensitivity of human lung cancer for vindesine. Eur J Cancer Clin Oncol 23:55–60.

    Article  PubMed  Google Scholar 

  20. Campling BG, Pym J, Baker HM, Cole SC, Lam Y-M. 1991. Chemosensitivity testing of small cell lung cancer using the MTT assay. Br J Cancer 63:75–83.

    Article  PubMed  CAS  Google Scholar 

  21. Volm M, Drings P, Hahn EW, Mattern J. 1988. Prediction of the clinical chemotherapeutic response of stage III lung adenocarcinoma patients by an in vitro short-term test. Br J Cancer 57:198–200.

    Article  PubMed  CAS  Google Scholar 

  22. Linn SC, Giaccone G, Van Kalken CK, Pinedo HM. 1992. P-glycoprotein mediated multidrug resistance and its clinical relevance in cancer treatment. FORUM Trends Exp Clin Med 2:642–657.

    Google Scholar 

  23. Lai S-L, Goldstein LJ, Gottesman MM, et al. 1989. MDR1 gene expression in lung cancer. J Natl Cancer Inst 81:1144–1150.

    Article  PubMed  CAS  Google Scholar 

  24. Shin HJC, Lee JS, Hong WK, Shin DM. 1992. Study of multidrug resistance (MDR1) gene in non-small-cell lung cancer. Anticancer Res 12:367–370.

    PubMed  CAS  Google Scholar 

  25. Holzmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB. 1992. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 84:1486–1491.

    Article  PubMed  CAS  Google Scholar 

  26. Schlaifer D, Laurent G, Chittal S, et al. 1990. Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers. Br J Cancer 62:177–182.

    Article  PubMed  CAS  Google Scholar 

  27. Finstad CL, Yin BWT, Gordon CM, Federici MG, Welt S, Lloyd KO. 1991. Some monoclonal antibody reagents (C219 and JSB-1) to P-glycoprotein contain antibodies to blood group A carbohydrate determinants: a problem of quality control for immunohistochemical analysis. J Histochem Cytochem 39:1603–1610.

    Article  PubMed  CAS  Google Scholar 

  28. Van der Valk P, Van Kalken CK, Ketelaars H, et al. 1990. Distribution of multidrug-resistance associated P-glycoprotein in normal and neoplastic human tissues. Ann Oncol 1:56–64.

    PubMed  Google Scholar 

  29. Brambilla E, Moro D, Gazzeri S, et al. 1991. Cytotoxic chemotherapy induces cell differentiation in small-cell lung carcinoma. J Clin Oncol 9:50–61.

    PubMed  CAS  Google Scholar 

  30. Radosevich JA, Robinson PG, Rittman-Grauer LS, et al. 1989. Immunohistochemical analysis of pulmonary and pleural tumors with the monoclonal antibody HYB-612 directed against the multidrug resistance (MDR1) gene product, P-glycoprotein. Tumor Biol 10: 252–257.

    Article  CAS  Google Scholar 

  31. Volm M, Bak M, Mattern J. 1988. Intrinsic drug resistance in a human lung carcinoma xenograft is associated with overexpression of multidrug-resistance DNA-sequences and of plasma membrane glycoproteins. Arzneim Forsch Drug Res 38(II):1189–1193.

    CAS  Google Scholar 

  32. Noonan KE, Beck C, Holzmayer TA, et al. 1990. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87:7160–7164.

    Article  PubMed  CAS  Google Scholar 

  33. Smit EF, De Vries EGE, Timmer-Bosscha H, et al. 1992. In vitro response of human small-cell lung cancer cell lines to chemotherapeutic drugs; no correlation with clinical data. Int J Cancer 51:72–78.

    Article  PubMed  CAS  Google Scholar 

  34. Masuda N, Fukuoka M, Matsui K, et al. 1991. Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer. J Natl Cancer Inst 83:1743–1748.

    Article  PubMed  CAS  Google Scholar 

  35. Carmichael J, Mitchell JB, DeGraff WG, et al. 1985. Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br J Cancer 57:540–547.

    Article  Google Scholar 

  36. Carney DM, Mitchell JB, Kinsella TJ. 1983. In vitro radiation and chemosensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. Cancer Res 43:2806–2811.

    PubMed  CAS  Google Scholar 

  37. Berendsen HH, De Leij L, De Vries EGE, et al. 1988. Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up. Cancer Res 48:6891–6899.

    PubMed  CAS  Google Scholar 

  38. De Vries EGE, Meijer C, Timmer-Bosscha H, Berendsen HH, De Leij L, Scheper RJ, Mulder NH. 1989. Resistance mechanisms in three human small cell lung cancer cell lines established from one patient during clinical follow-up. Cancer Res 49:4175–4178.

    PubMed  Google Scholar 

  39. Hida T, Ueda R, Takahashi T, et al. 1989. Chemosensitivity and radiosenstivity of small cell lung cancer cell lines studied by a newly developed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) hybrid assay. Cancer Res 49:4785–4790.

    PubMed  CAS  Google Scholar 

  40. Milroy R, Plumb JA, Batstone P, et al. 1992. Lack of expression of P-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients. Anticancer Res 12:193–200.

    PubMed  CAS  Google Scholar 

  41. Kasahara K, Yasuhiro F, Sugimoto Y, et al. 1992. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J Natl Cancer Inst 84:113–118.

    Article  PubMed  CAS  Google Scholar 

  42. Nielsen D, Skovsgaard T. 1992. P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines. Biochim Biophys Acta 1139:169–183.

    Article  PubMed  CAS  Google Scholar 

  43. Zijlstra JG, De Vries EGE, Mulder NH. 1987. Multifactorial drug resistance in an adriamycin-resistant human small cell lung cancer cell line. Cancer Res 47:1780–1784.

    PubMed  CAS  Google Scholar 

  44. Mirski SEL, Gerlach JH, Cole SPC. 1987. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 47:2594–2598.

    PubMed  CAS  Google Scholar 

  45. Baas F, Jongsma APM, Broxterman HJ, et al. 1990. Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line. Cancer Res 50:5392–5398.

    PubMed  CAS  Google Scholar 

  46. Reeve JG, Rabbitts PH, Twentyman PR. 1990. Non-P-glycoprotein mediated multidrug resistance with reduced EGF receptor expresssion in a human large cell lung cancer cell line. Br J Cancer 61:851–855.

    Article  PubMed  CAS  Google Scholar 

  47. Eijdems EWHM, Borst P, Jongsma APM, et al. 1992. Genetic transfer of non-P-glycoprotein-mediated multidrug resistance (MDR) in somatic cell fusion: Dissection of a compound MDR phenotype. Proc Natl Acad Sci USA 89:3498–3502.

    Article  PubMed  CAS  Google Scholar 

  48. Kuiper CM, Broxterman HJ, Baas F, et al. 1990. Drug transport variants without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin. J Cell Pharmacol 1:35–41.

    CAS  Google Scholar 

  49. Broxterman HJ, Schuurhuis GJ, Lankelma J, Baak JPA, Pinedo HM. 1990. Towards functional screening for multidrug resistant cells in human malignancies. In Drug Resistance: Mechanisms and Reversal, E. Mihich (ed.). John Libbey CIC: Rome, pp. 309–319.

    Google Scholar 

  50. Coley HM, Workman P, Twentyman PR. 1991. Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma cell line without P-glycoprotein hyperexpression. Br J Cancer 63:351–357.

    Article  PubMed  CAS  Google Scholar 

  51. Barrand MA, Broxterman HJ, Wright KA, Rhodes T, Twentyman PR. 1992. Immuno-detection of a 190 kD protein in atypical MDR cells derived from small cell and non-small cell lung tumours. Br J Cancer 65(Suppl XVI):21.

    Google Scholar 

  52. Versantvoort CHM, Twentyman PR, Barrand MA, Lankelma J, Pinedo HM, Broxterman HJ. 1992. Overexpression of 110 kD and 190 kD proteins in cancer cells may be involved in drug resistant phenotype. Proc Am Assoc Cancer Res 33:456.

    Google Scholar 

  53. Marquardt D, McCrone S, Center MS. 1990. Mechanism of multidrug resistance in HL60 cells: detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein. Cancer Res 50:1426–1430.

    PubMed  CAS  Google Scholar 

  54. Cole SPC. 1992. The 1991 Merck Frost Award. Multidrug resistance in small cell lung cancer. Can J Physiol Pharmacol 70:313–329.

    Article  PubMed  CAS  Google Scholar 

  55. Zaman GJR, Versantvoort CHM, Smit JJM, et al. 1993. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 53:1747–1750.

    PubMed  CAS  Google Scholar 

  56. Cole SPC. 1993. A novel ATP-binding cassette transporter gene overexpressed in multidrug-resistant human lung tumour cells. Proc Am Assoc Cancer Res 34:579.

    Google Scholar 

  57. Scheper RJ, Broxterman HJ, Scheffer GL, et al. 1993. Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53: 1475–1479.

    PubMed  CAS  Google Scholar 

  58. Cole SPC, Pinkoski MJ, Bhardwaj G, Deeley RG. 1992. Elevated expression of annexin (Lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. Br J Cancer 65:498–502.

    Article  PubMed  CAS  Google Scholar 

  59. Ford JM, Hait WN. 1990. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155–199.

    PubMed  CAS  Google Scholar 

  60. Versantvoort CHM, Schuurhuis GJ, Pinedo HM, Eekman CA, Kuiper CM, Lankelma JA, Broxterman HJ. 1993. Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer 68:939–946.

    Article  PubMed  CAS  Google Scholar 

  61. Schuurhuis GJ, Broxterman HJ, Cervantes A, Van Heijningen THM, De Lange JHM, Baak JPA, Pinedo HM, Lankelma J. 1989. Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. J Natl Cancer Inst 81:1887–1892.

    Article  PubMed  CAS  Google Scholar 

  62. Schuurhuis GJ, Broxterman HJ, De Lange JHM, et al. 1991. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br J Cancer 64:857–861.

    Article  PubMed  CAS  Google Scholar 

  63. Schuurhuis GJ, Broxterman HJ, Pinedo HM, et al. 1992. Multidrug resistance phenotype in acute myeloid leukemia, characterized by altered subcellular drug distribution and decreased drug accumulation, independent of P-glycoprotein. Proc Am Assoc Cancer Res 33:454.

    Google Scholar 

  64. Seidel A, Pest S, Kaufmann O, Dietel M. 1993. Intracellular distribution of cytostatic drugs in low degree resistant tumor cell lines and primary tumor cell preparations. Proc Am Assoc Cancer Res 34:25.

    Google Scholar 

  65. Versantvoort CHM, Broxterman HJ, Feller N, Dekker H, Kuiper CM, Lankelma J. 1992. Probing daunorubicin accumulation defects in non-P-glycoprotein expressing multidrug-resistant cell lines using digitonin. Int J Cancer 50:906–911.

    Article  PubMed  CAS  Google Scholar 

  66. Nygren P, Larsson R, Gruber A, Peterson C, Bergh J. 1991. Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression. Br J Cancer 64:1011–1018.

    Article  PubMed  CAS  Google Scholar 

  67. Larsson R, Bergh J, Nygren P. 1991. Combination of cyclosporin A and buthionine sulfoximine (BSO) as a pharmacological strategy for circumvention of multidrug resistance in small cell lung cancer cell lines selected for resistance to doxorubicin. Anticancer Res 11:455–460.

    PubMed  CAS  Google Scholar 

  68. Pommier Y. 1993. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother Pharmacol 32:103–108.

    Article  PubMed  CAS  Google Scholar 

  69. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT. 1988. Altered catalytic activity of DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27:8861–8869.

    Article  PubMed  CAS  Google Scholar 

  70. De Jong S, Kooistra AJ, De Vries EGE, Mulder NH, Zijlstra JG. 1993. Topoisomerase II as a target of VM-26 and 4′-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. Cancer Res 53:1064–1071.

    PubMed  Google Scholar 

  71. Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G. 1992. Multidrug sensitivity phenotype of lung cancer cells associated with topoisomerase II expression. Cancer Res 52:1666–1674.

    PubMed  CAS  Google Scholar 

  72. Tan KB, Mattern MR, Eng W-K, McCabe FL, Johnson RK. 1989. Nonreproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81:1732–1735.

    Article  PubMed  CAS  Google Scholar 

  73. Deffie AM, Bosman DJ, Goldenberg GJ. 1989. Evidence for a mutant allele of the gene for DNA topoisomerase II in adriamycin-resistant P388 murine leukemia cells. Cancer Res 49:6879–6882.

    PubMed  CAS  Google Scholar 

  74. Gudkov AV, Zelnick CR, Kazarov AR, Thimmapaya R, Suttle DP, Beck WT, Roninson IB. 1993. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II — interactive cytotoxic drugs, from human topoisomerase-II cDNA. Proc Natl Acad Sci USA 90:3231–3235.

    Article  PubMed  CAS  Google Scholar 

  75. Borst P. 1991. Genetic mechanisms of drug resistance. Reviews in Oncology. Acta Oncologica 30:87–105.

    Article  PubMed  CAS  Google Scholar 

  76. Haraf DJ, Devine S, Ihde DC, Vokes EE. 1992. The evolving role of systemic therapy in carcinoma of the lung. Semin Oncol 19(S11):72–87.

    PubMed  CAS  Google Scholar 

  77. Tsuruo T, Iida H, Tsukagoshi S, et al. 1981. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967–1972.

    PubMed  CAS  Google Scholar 

  78. Miller TP, Grogan TM, Dalton WS, et al. 1991. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. J Clin Oncol 9:17–24.

    PubMed  CAS  Google Scholar 

  79. Sonneveld P, Durie BGM, Lokhorst HM, et al. 1992. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340:255–259.

    Article  PubMed  CAS  Google Scholar 

  80. Pennock GD, Dalton WS, Roeske WR, et al. 1991. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 83:105–110.

    Article  PubMed  CAS  Google Scholar 

  81. Yahanda AM, Adler KM, Fisher GA, et al. 1992. Phase I trial of etoposide with cyclo-sporine as a modulator of multidrug resistance. J Clin Oncol 10:1624–1634.

    PubMed  CAS  Google Scholar 

  82. Boesch D, Gavériaux C, Jachez B, et al. 1991. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51:4226–4233.

    PubMed  CAS  Google Scholar 

  83. Figueredo A, Arnold A, Goodyear M, Findlay B, Neville A, Normandeau R, Jones RN. 1990. Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer. A phase I/II study. Cancer 65:1895–1902.

    Article  PubMed  CAS  Google Scholar 

  84. Abratt RP, Wilcox PA, Hewitson RH. 1987. Etoposide combination therapy for small cell carcinoma of the lung. Cancer Chemother Pharmacol 20:83–84.

    Article  PubMed  CAS  Google Scholar 

  85. Kerr DJ, Graham J, Cummings J, Morrison JG, Thompson GG, Brodie MJ, Kaye SB. 1986. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 18:239–242.

    Article  PubMed  CAS  Google Scholar 

  86. Lum BL, Kaubisch S, Yahanda AM, et al. 1992. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635–1642.

    PubMed  CAS  Google Scholar 

  87. Millward MJ, Cantwell BMJ, Munro NC, Robinson A, Corns PA, Harris AL. 1993. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br J Cancer 67:1031–1035.

    Article  PubMed  CAS  Google Scholar 

  88. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. 1993. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53:977–984.

    PubMed  CAS  Google Scholar 

  89. Hill BT, Deuchars K, Hosking LK, Ling V, Whelan RDH. 1990. Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X irradiation in vitro. J Natl Cancer Inst 82:607–612.

    Article  PubMed  CAS  Google Scholar 

  90. Mattern J, Efferth T, Volm M. 1991. Overexpression of P-glycoprotein in human lung carcinoma xenografts after fractionated irradiation in vivo. Radiat Res 127:335–338.

    Article  PubMed  CAS  Google Scholar 

  91. McClean S, Hosking LK, Hill BT. 1993. Dominant expression of multiple drug resistance after in vitro X-irradiation exposure in intraspecific Chinese hamster ovary hybrid cells. J Natl Cancer Inst 85:48–53.

    Article  PubMed  CAS  Google Scholar 

  92. Reeve JG, Rabbits PH, Twentyman PR. 1989. Amplification and expression of mdrl gene in a multidrug resistant variant of small cell lung cancer cell line NCI-H69. Br J Cancer 60:339–342.

    Article  PubMed  CAS  Google Scholar 

  93. Minato K, Kanzawa F, Nishio K, Nakagawa K, Fujiwara Y, Saijo N. 1990. Characterization of an etoposide-resistant human small-cell lung cancer line. Cancer Chemother Pharmacol 26:313–317.

    Article  PubMed  CAS  Google Scholar 

  94. Keizer HG, Schuurhuis GJ, Broxterman HJ, et al. 1989. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res 49:2988–2993.

    PubMed  CAS  Google Scholar 

  95. Supino R, Binaschi M, Capranico G, Gambetta RA, Prosperi E, Sala E, Zupino F. 1993. A study of cross-resistance pattern and expression of molecular markers of multidrug resistance in a human small-cell lung-cancer cell line selected with doxorubicin. Int J Cancer 54:309–314.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Henk J. Broxterman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carolien H. M. Versantvoort
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sabine C. Linn
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Oncology 5074, Rigshospitalet, 9 Blegdamsvej, DK-2100, Copenhagen, Denmark

    Heine H. Hansen

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer Science+Business Media New York

About this chapter

Cite this chapter

Broxterman, H.J., Versantvoort, C.H.M., Linn, S.C. (1994). Multidrug resistance in lung cancer. In: Hansen, H.H. (eds) Lung Cancer. Cancer Treatment and Research, vol 72. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2630-8_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2630-8_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6128-2

  • Online ISBN: 978-1-4615-2630-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation